“You may choose to look the other way, but you can never say again that you did not know.”
— William Wilberforce
Biotechnology company Novavax announced that it has made a modification to an existing contract with the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DoD) to provide up to 1.5 million more doses of its Nuvaxovid COVID-19 vaccine (also known as “NVX-CoV2373” and “Covovax”), in addition to the 3.2 million […]
Froedtert Health, a health care system headquartered in Wauwatosa, Wisconsin, is withdrawing religious and medical exemptions held by employees who had originally refused to get the messenger RNA (mRNA) COVID-19 shots. The company informed its employees that they must now get vaccinated with the recently approved Novavax’s COVID vaccine NVX-CoV2373 (also known as “Nuvaxovid” and […]
Opinion | On July 13, 2022, the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) to Novavax to distribute its experimental two-dose NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine for use by adults. The decision was expected, given the favorable recommendation by the FDA’s Vaccines and Related Biological Products Advisory […]
Despite concerns about the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining of the heart) following vaccination with Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine, the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted on June 6, […]
Novavax, one of the worst performers on Wall Street, and that is after an FDA warning on its COVID vaccine. Year to date, down 68 percent. Of course, that coming as a result of the FDA out with their analysis from Novavax’s data that they submitted for the emergency use filing for the meeting coming […]
Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine has been authorized for distribution in the European Union (E.U.), making it the fifth COVID vaccine available for use in the E.U. Approved for people over 18 years old, Nuvaxoid is the first protein subunit COVID vaccine to be approved for use.1 2 The […]
American pharmaceutical and biotechnology company Moderna, Inc., which partnered with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) to develop an mRNA COVID-19 vaccine being distributed in the United States under an Emergency Use Authorization (EUA) announced that it is developing a combined single-dose booster vaccine for COVID-19 and seasonal influenza.1 In a […]
Biotechnology company Novavax, Inc. of Gaithersburg, Maryland recently made public the results of the Phase 1 part of a Phase 1/2 human clinical trial for its experimental NVX-CoV2373 vaccine for COVID-19. According to Novavax, “NVX‑CoV2373 was created using Novavax’s recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’s […]